Orphan Disease Treatment Institute Office Opens inside Daiichi Sankyo Shinagawa R&D Center

Tokyo, Japan (April 1, 2013) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today the opening of the office of the Orphan Disease Treatment Institute Co., Ltd. (hereafter, Orphan Disease Treatment Institute) inside the Daiichi Sankyo Shinagawa R&D center. The establishment of the Orphan Disease Treatment Institute was announced on February 14, 2013, in a press release entitled, “Daiichi Sankyo Announces Development of Nucleic Acid Treatment for Duchenne Muscular Dystrophy Utilizing Proprietary Technology.”

With today’s office opening, the new company can now begin to fully undertake development of a treatment for Duchenne muscular dystrophy.

The Orphan Disease Treatment Institute was financed through joint investment from Innovation Network Corporation of Japan, a fund managed by Mitsubishi UFJ Capital Co., Ltd and Daiichi Sankyo.

Profile of Orphan Disease Treatment Institute Co., Ltd.

1. Company name: Orphan Disease Treatment Institute Co., Ltd.

2. Date of establishment: March 1, 2013

3. Location: Hiromachi 1-2-58, Shinagawa-ku, Tokyo
   (inside the Daiichi Sankyo Shinagawa R&D center)

4. Management structure
   Makoto Hanada, President
   Hidemi Masumura, Director
   Shigeyuki Tsuchida, Director
   Nobutake Morii, Director
   Yoshitaka Fukui, Auditor

5. Capital/capital reserves: 450 million yen


7. Employees: 2

###